Is LIXT or LLY more undervalued in 2026?

CirclFi compares Lixte Biotechnology Holdings, I (LIXT) and Eli Lilly and Company (LLY) using 13 institutional-grade valuation models. LIXT has a Quality of Company score of 4.2/10 while LLY scores 10.0/10.

Which is a better buy — LIXT or LLY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LIXT and LLY valuations compare?

LIXT at $6.25 and LLY at $1105.00 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LIXT vs LLY Valuation Comparison 2026 — Intrinsic Value Analysis

LIXT

Pharmaceutical Preparations

Lixte Biotechnology Holdings, I

Quality

4.2

out of 10

Value Trap

SAFE

Price

$6.25

Last close

Models

7/13

Active

LLY

Pharmaceutical Preparations

Eli Lilly and Company

Quality

10.0

out of 10

Value Trap

SAFE

Price

$1105.00

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	LIXT Fair Value	LIXT Upside	LLY Fair Value	LLY Upside
Bayesian DCF	Intrinsic	$1.53	-75.5%	$275.28	-75.1%
Earnings Power Value	Intrinsic	—	—	$192.34	-82.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.71	-88.6%	$34.96	-96.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LIXT vs LLY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LIXT vs LLY — Which Stock Is More Undervalued?

LLY scores higher with a 10.0/10 quality rating vs LIXT's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lixte Biotechnology Holdings, I (LIXT) and Eli Lilly and Company (LLY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LIXT currently trades at $6.25 with a QOC of 4.2/10, while LLY trades at $1105.00 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).